Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
2016 Standout
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
2013
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
2018 StandoutNobel
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma
2013
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Generation of knock-in primary human T cells using Cas9 ribonucleoproteins
2015 StandoutNobel
Allogeneic Stem-Cell Transplantation As Salvage Therapy for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Relapsing After an Autologous Stem-Cell Transplantation: An Analysis of the European Group for Blood and Marrow Transplantation Registry
2011
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
2010 Standout
Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas
2013
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
2017 Standout
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
Alteration of enzyme specificity by computational loop remodeling and design
2009 StandoutNobel
Guidelines for the welfare and use of animals in cancer research
2010 Standout
CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes
2016
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
2020 Standout
Cancer treatment and survivorship statistics, 2022
2022 Standout
HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry
2014 Standout
The biology of human natural killer-cell subsets
2001 Standout
A guide to genome engineering with programmable nucleases
2014 Standout
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
2017
Anthracycline-Induced Cardiomyopathy
2010
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin’s Lymphoma
2016
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
2017
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension
1996 Standout
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
2003 Standout
Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection
2018 StandoutNobel
R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study
2008
DNA cleavage enzymes for treatment of persistent viral infections: Recent advances and the pathway forward
2014
Primary Pulmonary Hypertension
1997 Standout
Engineering lymphocyte subsets: tools, trials and tribulations
2009
Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors
2011
A Cas9 Ribonucleoprotein Platform for Functional Genetic Studies of HIV-Host Interactions in Primary Human T Cells
2016 StandoutNobel
Delivery technologies for cancer immunotherapy
2019 Standout
Antibody therapy of cancer
2012 Standout
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method
2009
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies
2013
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
2013
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study
2001 Standout
Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease?
2007
Intensified Prophylaxis of Febrile Neutropenia with Ofloxacin Plus Rifampin During Severe Short-Duration Neutropenia in Patients with Lymphoma
1999
Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study
2016
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2012
Allogeneic transplantation of blood stem cells: Coming of age?
2001
PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
2016
Diffuse large B-cell lymphoma—treatment approaches in the molecular era
2013
Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
2015
Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy
2011
Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial
2012
Gene Map of the HLA Region, Graves’ Disease and Hashimoto Thyroiditis, and Hematopoietic Stem Cell Transplantation
2015
Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA
2015 StandoutNobel
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
2014 Standout
Diffuse large B-cell lymphoma
2013
The prognostic landscape of genes and infiltrating immune cells across human cancers
2015 Standout
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
2017 Standout
The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy
2019 StandoutNobel
Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma
2017 Standout
Chimeric antigen receptor T-cell therapies for lymphoma
2017
Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies
2013
Efficient Clinical Scale Gene Modification via Zinc Finger Nuclease–Targeted Disruption of the HIV Co-receptor CCR5
2013
Adoptive Immunotherapy for Cancer or Viruses
2014
Bacteremia Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in a Pediatric Oncology Ward: Clinical Features and Identification of Different Plasmids Carrying both SHV-5 and TEM-1 Genes
1999
The side effects of platinum-based chemotherapy drugs: a review for chemists
2018 Standout
Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
2006 Standout
Regulatory T Cells and Human Disease
2020 StandoutNobel
Acute Myeloid Leukemia
2015 Standout
In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism
2023 StandoutNobel
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
2018
Pharmacologically induced Pulmonary Vasodilatation in Children and Young Adults with Primary Pulmonary Hypertension
1986
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells
2005
Extended-Spectrum β-Lactamases: a Clinical Update
2005 Standout
Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP
2012
Outcomes of patients with relapsed/refractory diffuse large B‐cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era
2013
2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
2002 Standout
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
2011
Treatment Selection and Survival Outcomes in Early-Stage Diffuse Large B-Cell Lymphoma: Do We Still Need Consolidative Radiotherapy?
2015
Chimeric Antigen Receptor Therapy
2018 Standout
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
2014
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
2008
Comparative toxicities of 3 platinum‐containing chemotherapy regimens in relapsed/refractory lymphoma patients
2016
Cancer treatment and survivorship statistics, 2019
2019 Standout
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment
2011
Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants
2002 StandoutScience
Transformed follicular non-Hodgkin lymphoma
2014
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
2015 Standout
Role of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation
1999
Pixantrone–Rituximab Versus Gemcitabine–Rituximab In Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
2016
Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering
2023 StandoutNobel
Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy
2015
Works of Bertram Glaß being referenced
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
2010
Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma
2014
Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial
2014
Graft‐versus‐leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells
1996
B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression
2010
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)
2012
Four versus six courses of a dose‐escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation
2005
Management of infections during intensive treatment of hematologic malignancies
1997
Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectors
2004
The morphogenesis and reversibility of experimental hyperkinetic pulmonary vascular lesions in the dog
1965
Allogeneic Peripheral Blood Progenitor Cell Transplantation in a Murine Model: Evidence for an Improved Graft-Versus-Leukemia Effect
1997
High-dose chemotherapy followed by allogeneic stem cell transplantation in high-risk relapsed and refractory aggressive non-Hodgkin lymphoma: Results of a prospective study of the German high-grade non-Hodgkin lymphoma study group.
2012
Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era
2010
Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study
2013
Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma
2012
R-ICE Versus R-DHAP in Relapsed Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Followed by Stem Cell Transplantation and Maintenance Treatment with Rituximab or Not: First Interim Analysis on 200 Patients. CORAL Study.
2007
Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma.
2009
Outcome of Elderly Patients with DLBCL Failing R-CHOP: The Role of Rituximab and High Dose Therapy in Second Line Treatment. A Retrospective Analysis From the RICOVER 60 Trial.
2009
High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis
2013
Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice
2001
Impact of Rituximab and Radiotherapy on Outcome of Patients With Aggressive B-Cell Lymphoma and Skeletal Involvement
2013